Publications by authors named "H C Kung"
Radioactive prostate-specific membrane antigen (PSMA)-targeting agents are clinically useful for the diagnosis and treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine-differentiated prostate cancer (NEPC), a highly aggressive subtype that is strongly associated with a poor clinical prognosis, may present with reduced PSMA expression and evade detection with PSMA-targeted agents. Several studies have shown elevated uptake of somatostatin receptor 2 (SSTR2) ligands in PSMA-negative NEPC.
View Article and Find Full Text PDFFibroblast activation protein (FAP), which is overexpressed in cancer-associated fibroblasts (CAFs), represents a promising target for cancer diagnosis and therapy. Hypoxia is a common feature of solid tumors. A bivalent agent, DOTA-NI-FAPI-04 (), was developed by incorporating hypoxia-sensitive nitroimidazole (NI) into the FAP-targeting agent FAPI-04.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to compare a new GLP-1R-targeted PET agent, 68 Ga-HBED-CC-exendin-4, with an older version, 68 Ga-NOTA-exendin-4, for locating insulinoma in patients with hyperinsulinemic hypoglycemia.
- Both agents demonstrated 100% sensitivity, but 68 Ga-HBED-CC-exendin-4 had a lower tumor uptake value compared to 68 Ga-NOTA-exendin-4, although both maintained similar tumor-to-background ratios.
- The new agent also showed a significant reduction in renal accumulation, potentially enhancing the detection of tumors located near the kidney.
Article Synopsis
- Bisphosphonates are crucial for treating bone tumors by preventing bone loss; this study explores the effectiveness of a new bisphosphonate, [Lu]Lu-P15-073, in radioligand therapy for bone metastases.
- Ten patients aged 35 to 75 with bone metastases received a single dose of [Lu]Lu-P15-073, showing rapid accumulation in tumors and minimal impact on other organs, while demonstrating safety through blood tests and pain assessments.
- The results indicate that the treatment was well-tolerated, significantly reduced pain in most patients, and suggests that [Lu]Lu-P15-073 could be a promising option for managing bone metastases.
Article Synopsis
- D6-[F]FP-(+)-DTBZ is a new imaging agent designed for PET scans that helps diagnose Parkinson's disease (PD) by tracking VMAT2 transporters in the brain.
- In a study, this radioligand demonstrated efficient production, high purity, and distinct uptake in brain regions associated with PD, showing a greater effectiveness compared to its non-deuterated counterpart.
- The findings suggest that D6-[F]FP-(+)-DTBZ could serve as a safer, more effective tool for monitoring VMAT2 levels in monoamine neurons, potentially improving PD diagnosis.